The approval of Bionano Genomics' products by China's National Medical Products Administration, facilitated by their partner A-smart Medtech, is a positive development for the company. This could potentially open up a large new market for their products, which could lead to increased sales and revenue. Therefore, this news is likely to have a positive impact on Bionano Genomics' stock price in the short term.